Breaking News Instant updates and real-time market news.

AMAG

Amag Pharmaceuticals

$15.38

0.23 (1.52%)

, SLDB

Solid Biosciences

$32.09

0.47 (1.49%)

10:25
01/09/19
01/09
10:25
01/09/19
10:25

JPMorgan to hold a conference

37th Annual Healthcare Conference will be held in San Francisco on January 7-10 with webcasted company presentations to begin on January 9 at 10:30 am; not all company presentations may be webcasted. Webcast Link

AMAG

Amag Pharmaceuticals

$15.38

0.23 (1.52%)

SLDB

Solid Biosciences

$32.09

0.47 (1.49%)

REPL

Replimune Group

$10.54

0.21 (2.03%)

ABBV

AbbVie

$90.78

0.01 (0.01%)

IDRA

Idera Pharmaceuticals

$3.72

-0.01 (-0.27%)

IMGN

ImmunoGen

$5.54

-0.01 (-0.18%)

ZLAB

Zai Lab

$23.19

0.35 (1.53%)

IPSEY

Ipsen

$0.00

(0.00%)

EDIT

Editas Medicine

$25.95

0.5 (1.96%)

SRRK

Scholar Rock

$20.63

(0.00%)

IFRX

InflaRx

$35.79

(0.00%)

AMRN

Amarin

$14.38

0.45 (3.23%)

AKBA

Akebia

$6.49

-0.11 (-1.67%)

PKI

PerkinElmer

$79.53

0.75 (0.95%)

ELAN

Elanco

$33.25

0.82 (2.53%)

XRAY

Dentsply Sirona

$40.00

0.58 (1.47%)

NVRO

Nevro

$40.82

1.03 (2.59%)

HALO

Halozyme

$15.29

-0.04 (-0.26%)

SNNA

Sienna Biopharmaceuticals

$3.02

0.02 (0.67%)

ACAD

Acadia

$19.19

0.67 (3.62%)

AXDX

Accelerate Diagnostics

$14.56

0.11 (0.76%)

ICPT

Intercept

$112.50

1.58 (1.42%)

OXFD

Oxford Immunotec

$14.34

0.21 (1.49%)

SSNLF

Samsung

$0.00

(0.00%)

MDSO

Medidata

$68.18

1.28 (1.91%)

WELL

Welltower

$69.75

-0.5 (-0.71%)

OMCL

Omnicell

$64.44

0.65 (1.02%)

LJPC

La Jolla

$6.00

0.56 (10.29%)

ARAY

Accuray

$3.70

0.08 (2.21%)

LMNX

Luminex

$24.56

0.33 (1.36%)

  • 09

    Jan

  • 09

    Jan

  • 15

    Jan

  • 16

    Jan

  • 17

    Jan

  • 17

    Jan

  • 22

    Jan

  • 22

    Jan

  • 23

    Jan

  • 24

    Jan

  • 25

    Jan

  • 28

    Jan

  • 30

    Jan

  • 31

    Jan

  • 04

    Feb

  • 25

    Feb

  • 23

    Mar

  • 18

    May

AMAG Amag Pharmaceuticals
$15.38

0.23 (1.52%)

12/13/18
PIPR
12/13/18
NO CHANGE
Target $20
PIPR
Neutral
Piper stays Neutral on Amag following Perosphere acquisition
Piper Jaffray analyst Christopher Raymond keeps a Neutral rating on Amag Pharmaceuticals following this morning's announcement that the company will acquire Perosphere Pharmaceuticals and global rights to its anticoagulant reversal agent, ciraparantag. The acquisition seems to be a good strategic fit with Feraheme, though whether the profile is sufficiently differentiated to drive adoption over other novel oral anticoagulant reversal agents "remains to be seen," Raymond tells investors in a research note. The analyst thinks a deal outside of women's health is a good move for Amag, but he continues to have concerns on Makena, Intrarosa and the rest of the company's women's health portfolio.
11/13/18
PIPR
11/13/18
NO CHANGE
Target $20
PIPR
Neutral
Piper remains 'cautious' on Amag following Vyleesi timeline delay
Piper Jaffray analyst Christopher Raymond keeps a Neutral rating on Amag Pharmaceuticals after the company's disclosure of a delay to Vyleesi timelines as a result of an FDA request for additional clinical safety data. The analyst says that while management has touted this drug's potential as a major contributor, he remains "skeptical," given the uncertainty around the female sexual dysfunction market and the drug's side effect and convenience profile. Raymond is keeping Vyleesi out of his model and remains "cautious" on Amag shares with a $20 price target.
01/07/19
PIPR
01/07/19
NO CHANGE
PIPR
Piper says remain on sidelines after Amag pre-releases weak Q4
Piper Jaffray analyst Christopher Raymond maintained a Neutral rating and $20 price target on AMAG Pharmaceuticals after the company pre-released below-consensus Q4 results and initial FY19 guidance that broadly brackets consensus expectations. The analyst also has concerns about Vyleesi, which has a pushed out PDUFA date of June 23, 2019, and Makena, as there is another generic now on the market, and recommends staying on the sidelines.
11/06/18
JPMS
11/06/18
DOWNGRADE
Target $18
JPMS
Underweight
JPMorgan downgrades Amag to Underweight on product uncertainties
JPMorgan analyst Jessica Fye downgraded Amag Pharmaceuticals to Underweight from Neutral and lowered her price target for the shares to $18 from $20. The analyst sees "uncertainties across multiple product lines" that she believes will lead the stock to underperform following Amag's Q3 results and preliminary negative 2019 profit view. Supply issues add a wrinkle in the Makena outlook, Fye tells investors in a research note. The analyst admits, however, that the company's ultimate 2019 financial results "may not be quite as bad as feared" and that the stock is "fairly washed out." Nonetheless, Fye views Amag as a "show me" story with 2019 set up as an investment year.
SLDB Solid Biosciences
$32.09

0.47 (1.49%)

12/10/18
BTIG
12/10/18
INITIATION
BTIG
Neutral
Solid Biosciences initiated with a Neutral at BTIG
BTIG analyst Timothy Chiang initiated Solid Biosciences with a Neutral rating. The analyst notes that the company is one of three players with a micro-dystrophin gene therapy for the treatment of Duchenne Muscular Dystrophy, or DMD, but also does not expect that program to gain approval until 2022. Chiang further states that he anticipates the peak sales potential for gene therapies for DMD to take place in 2024-2025 and believes that the current valuation on Solid Biosciences reflects those expectations.
12/10/18
12/10/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Solid Biosciences (SLDB) initiated with a Neutral at BTIG. 2. Canada Goose (GOOS) initiated with a Positive at Susquehanna. 3. Internap (INAP) initiated with a Buy at Jefferies. 4. Vapotherm (VAPO) initiated with an Outperform at William Blair and a Buy at BTIG, Canaccord, and BofA/Merrill. 5. Gold Fields (GFI) initiated with an Underperform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/28/18
BTIG
12/28/18
NO CHANGE
Target $190
BTIG
Buy
Sarepta's recent weakness represents 'buying opportunity', says BTIG
BTIG analyst Timothy Chiang kept his Buy rating and $190 price target on Sarepta (SRPT), noting that while the stock was among the best performing biotech names this year, its recent weakness represents a "potential buying opportunity". The analyst believes that the company's AAVrh74 micro-dystrophin gene therapy for the treatment of Duchenne Muscular Dystrophy program leads those of Pfizer (PFE) and Solid Biosciences (SLDB) and expects Sarepta to reach about $2B in peak U.S. sales by 2024.
01/02/19
JPMS
01/02/19
NO CHANGE
JPMS
Overweight
JPMorgan a buyer of Sarepta into next week's healthcare conference
Both Sarepta Therapeutics (SRPT) and Solid Biosciences (SLDB) have important clinical events in Q1 of 2019, JPMorgan analyst Anupam Rama tells investors in a research note. Preliminary data from Solid's ongoing phase 1/2 IGNITE-DMD trial of SGT-001 micro-dystrophin gene therapy in Duchenne muscular dystrophy are expected in the quarter, the analyst says. He believes these data will have important read-through to the micro-dystrophin space, including Sarepta's program. Further, Sarepta will be presenting 60-day biopsy data from Cohort 1 in early-2019 from the ongoing phase 1/2a MYO-101 beta-sarcoglycan gene therapy program in limb-girdle muscular dystrophy type 2E, adds Rama. The analyst is a buyer of Sarepta into his firm's healthcare conference next week and continues to view Solid as a "show me" story.
REPL Replimune Group
$10.54

0.21 (2.03%)

08/14/18
LEER
08/14/18
INITIATION
Target $25
LEER
Outperform
Replimune Group initiated with an Outperform at Leerink
Leerink analyst Jonathan Chang started Replimune Group with an Outperform rating and $25 price target. While the company is still in the early stages of clinical development, the analyst has a positive long-term view on the stock because of Replimune Group's experienced management team, clear clinical strategy moving into combination trials, and potential broad applicability to injectable tumors. Chang also believes that it has a lower risk profile when compared to other oncolytic virus companies.
08/14/18
BMOC
08/14/18
INITIATION
Target $31
BMOC
Outperform
Replimune Group initiated with an Outperform at BMO Capital
As reported earlier, BMO Capital analyst Do Kim initiated Replimune with an Outperform rating and a price target of $31, saying its platform has been "significantly de-risked" based on its "structural similarity to T-Vec, the only FDA-approved oncolytic virus." The analyst contends that Replimune's RP1 is better than T-Vec, with a " more potent HSV-1 strain and addition of fusogenic protein GALV", and can deliver on rising expectations for oncolytic viruses helped by the advent of immunotherapy.
08/14/18
08/14/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Hudbay Minerals (HBM) reinstated with a Neutral at BofA/Merrill. 2. Establishment Labs (ESTA) initiated with a Buy at BTIG and Jefferies and an Outperform at Cowen. 3. Yext (YEXT) initiated with a Buy at SunTrust. 4. Akebia (AKBA) initiated with an Outperform at Raymond James. 5. Replimune Group (REPL) was initiated with an Outperform at Leerink and BMO Capital as well as an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/14/18
BMOC
08/14/18
INITIATION
Target $31
BMOC
Outperform
Replimune Group initiated with an Outperform at BMO Capital
ABBV AbbVie
$90.78

0.01 (0.01%)

01/03/19
01/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Hold from Buy at Jefferies and Loop Capital, as well as to Neutral from Outperform at Macquarie. 2. Genesee & Wyoming (GWR) downgraded to Equal Weight from Overweight at Stephens with analyst Justin Long citing his view that a re-expansion in valuation multiples could be more challenging in the near-term given North American volume headwinds in the short line network, unknowns around the PSR impact and more concerning international macro data points. 3. Lumber Liquidators (LL) downgraded to Hold from Buy at Loop Capital with analyst Laura Champine saying she reduced her margin forecast to reflect a promotional environment. 4. American Electric (AEP) downgraded to Neutral from Buy at Mizuho with analyst Paul Fremont citing valuation. 5. AbbVie (ABBV) downgraded to Neutral from Buy at BofA/Merrill with analyst Jason Gerberry saying he sees "limited upside to shares" relative to his price objective and also cites a more "unfavorable macro backdrop for companies with high single product concentration risk." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/03/19
BOFA
01/03/19
DOWNGRADE
Target $95
BOFA
Neutral
AbbVie downgraded to Neutral from Buy at BofA/Merrill
As noted earlier, BofA/Merrill analyst Jason Gerberry downgraded AbbVie to Neutral from Buy and lowered his price target to $95 from $98 as part of his broader research note on the Phamaceuticals sector partially titled "Preference for value, defensive + pipeline optionality". The analyst sees "limited upside to shares" relative to his price objective and also cites a more "unfavorable macro backdrop for companies with high single product concentration risk". Gerber believes that AbbVie would have to "meaningfully beat consensus forecasts on key new product launches" to reduce investor concerns over the loss of exclusivity for Humira and Imbruvica.
12/26/18
STPT
12/26/18
INITIATION
STPT
Buy
AbbVie initiated with a Buy at Standpoint Research
Standpoint Research analyst Ronnie Moas initiated AbbVie with a Buy rating.
01/03/19
BOFA
01/03/19
DOWNGRADE
BOFA
Neutral
AbbVie downgraded to Neutral from Buy at BofA/Merrill
IDRA Idera Pharmaceuticals
$3.72

-0.01 (-0.27%)

09/24/18
09/24/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Idera Pharmaceuticals (IDRA) initiated with an Overweight at Barclays. 2. Caesars (CZR) Entertainment initiated with a Sell at UBS. 3. GreenTree Hospitality (GHG) initiated with a Neutral at Goldman Sachs. 4. AMD (AMD) initiated with an Outperform at RBC Capital. 5. Vonage (VG) assumed with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/24/18
LEHM
09/24/18
INITIATION
Target $14
LEHM
Overweight
Idera Pharmaceuticals initiated with an Overweight at Barclays
Barclays analyst Gena Wang started Idera Pharmaceuticals with an Overweight rating and $14 price target. Tilsotolimod, when coupled with ipilimumab, has shown encouraging initial activity in PD-1 refractory melanoma patients, Wang tells investors in a research note. The analyst sees a favorable risk/reward profile into upcoming data readouts.
08/15/18
08/15/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cision (CISN) initiated with an Outperform at William Blair. 2. ObsEva (OBSV) resumed with an Outperform at Leerink. 3. Idera Pharmaceuticals (IDRA) resumed with an Overweight at JPMorgan. 4. DTE Energy (DTE) initiated with an Equal Weight at Barclays. 5. Tellurian (TELL) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/17/18
WEDB
12/17/18
NO CHANGE
Target $16
WEDB
Outperform
Wedbush 'positive' on Idera's Phase 2 study data
Wedbush analyst Robert Driscoll reiterated an Outperform rating and $16 price target on Idera Pharmaceuticals after the company updated results from the ongoing Phase 2 study of tilsotolimod plus ipilumumab in patients with PD-1 refractory melanoma. In a research note to investors, Driscoll says he remains "positive" on the study data, which he believe supports the ongoing Phase 3, and adds that ORR has tracked slightly lower than the previous data cut, but he believes 29.4% remains clinically meaningful with the potential to improve as tumor reductions continue to evolve over time.
IMGN ImmunoGen
$5.54

-0.01 (-0.18%)

11/27/18
HCWC
11/27/18
NO CHANGE
HCWC
Buy
ImmunoGen CFO resignation not based on current role, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay says the resignation of ImmunoGen (IMGN) CFO David Johnston after the executive was found guilty for civil securities fraud has little to do with the execution of his current responsibilities, but a reflection of his tenure with Aveo Pharmaceuticals (AVEO) pharmaceuticals between 2007 and 2012. Given that a potential guilty verdict was always a possibility, the analyst anticipates a potential replacement "in the not so distant future." With ImmunoGen having made "significant strides" over the past five years, and now closer to commercialization with mirvetuximab Phase 3 readout anticipated during the first half of 2019, any potential replacement might come with prior oncology commercialization experience, and might be a better fit with future needs of the company, Chattopadhyay tells investors in a research note titled "Water Under the old AVEO Bridge." He admits, however, that the resignation is publicity ImmunoGen "could have done without." Chattopadhyay keeps a Buy rating on ImmunoGen with an $18 price target.
12/02/18
PIPR
12/02/18
NO CHANGE
Target $14
PIPR
Overweight
'Solid' early single agent activity for ImmunoGen '632, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro notes that ImmunoGen presented updates from the Phase I trials of both IMGN632 and IMGN779in r/r AML and BPDCN at ASH this weekend. While the aanalyst acknowledges that some may be disappointed with the slight dip in CR/CRi rate for '632 and the lack of dose response, he finds the clear anti-leukemic activity at the lower, more tolerable doses notable and sees this as a positive first full look for this program. '779 still looks to be struggling to find an active dose, Catanzarro contends, adding that he is unsure whether higher doses will elicit enough of an increase in activity without increased toxicity that would warrant further monotherapy development. He reiterates an Overweight rating and $14 price target on the shares.
11/01/18
PIPR
11/01/18
NO CHANGE
Target $15
PIPR
Overweight
ImmunoGen data give 'very positive' first look at IMGN632, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro said the abstract for IMGN632 to be presented by ImmunoGen at the ASH meeting on its Phase 1 trial of IMGN632 in relapsed/refractory acute myeloid leukemia gives a "very positive first look," though he adds that he views the program as carrying significant clinical risk given the novel payload and prior failure of a similar drug. Catanzaro has an Overweight rating and $15 price target on ImmunoGen shares.
09/17/18
GUGG
09/17/18
INITIATION
GUGG
Guggenheim calls Array, Deciphera, ImmunoGen top biotech picks
Guggenheim initiated coverage of the biotechnology sector, initiating and assuming coverage of 17 biotechnology stocks, and saying it is bullish on the sector longer term and expects continued growth. The firm's coverage focuses on the oncology therapeutic category, with Guggenheim calling Array Biopharma (ARRY), Deciphera Pharmaceuticals (DCPH), and ImmunoGen (IMGN), which all have key catalysts coming in the first half or 2019, its top picks.
ZLAB Zai Lab
$23.19

0.35 (1.53%)

02/14/18
JPMS
02/14/18
UPGRADE
Target $35
JPMS
Overweight
Zai Lab upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Zai Lab to Overweight and raised his price target for the shares to $35 from $32. The analyst continues to view the company as an attractive healthcare emerging markets story in China, and now believes shares represent an attractive long-term entry point. The analyst adds that the FPA144 deal is an "underappreciated oncology tuck-in, with a meaningful target market opportunity."
06/21/18
LEER
06/21/18
INITIATION
Target $43
LEER
Outperform
Zai Lab assumed with an Outperform at Leerink
Leerink analyst Jonathan Chang assumed coverage of Zai Lab with an Outperform rating and $43 price target as he believes it is well-positioned to execute.
11/21/18
JEFF
11/21/18
INITIATION
Target $34
JEFF
Buy
Zai Lab initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft started Zai Lab with a Buy rating and $34 price target. The analyst likes the company's structure of forming partnerships around assets that are already clinically de-risked. The partnerships reduce risk and allow Zai Lab to accelerate a drug's path to market in China, Raycroft tells investors in a research note.
IPSEY Ipsen
$0.00

(0.00%)

09/28/18
GSCO
09/28/18
INITIATION
GSCO
Sell
Ipsen initiated with a Sell at Goldman Sachs
09/21/18
PIPR
09/21/18
NO CHANGE
Target $29
PIPR
Overweight
Piper Jaffray reiterates Overweight rating on Exelixis after CHMP decision
After Ipsen (IPSEY) announced a positive CHMP decision for Cabometyx as a monotherapy for the treatment of hepatocellular carcinoma, Piper Jaffray analyst Edward Tenthoff noted that Exelixis (EXEL) is eligible for tiered royalties of 22-26% after $100M in sales of the drug in Europe. He expects final EMA approval in coming months and also expects the FDA to approve Cabometyx in liver cancer by the January 14 PDUFA date, Tenthoff tells investors. He reiterated an Overweight rating and $29 price target on Exelixis shares.
10/08/18
JPMS
10/08/18
DOWNGRADE
JPMS
Underweight
Ipsen downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser downgraded Ipsen to Underweight with a price target of EUR 120. The analyst believes the risk/reward is skewed to the downside with the shares "priced for perfection."
EDIT Editas Medicine
$25.95

0.5 (1.96%)

07/18/18
JEFF
07/18/18
NO CHANGE
Target $40
JEFF
Buy
Study in Nature Biotech has limited readthrough to Intellia, says Jefferies
A new Nature Biotech publication highlights important safety points, but due to the methods/model systems used, the paper has limited readthrough to Intellia Therapeutics (NTLA), Editas Medicine (EDIT) and Crispr Therapeutics (CRSP) programs advancing to the clinic, Jefferies analyst Maury Raycroft tells investors in a research note. The analyst believes the experiments used in the paper were not representative and may not have direct implications to current gene-editing clinical-directed strategies. The paper is another example of using a non-optimal model system with too many variables, Raycroft contends. He keeps a Buy rating on Intellia with a $40 price target.
10/09/18
GUGG
10/09/18
INITIATION
GUGG
Neutral
Editas Medicine initiated with a Neutral at Guggenheim
Guggenheim analyst Whitney Ijem initiated Editas Medicine with a Neutral rating, calling the company's potential "mostly theoretical at this point as the company has yet to identify programs where these assets can be uniquely deployed."
09/21/18
RAJA
09/21/18
INITIATION
Target $40
RAJA
Outperform
Editas Medicine initiated with an Outperform at Raymond James
Raymond James analyst Steven Seedhouse initiated Editas Medicine with an Outperform and $40 price target saying data comps for lead indication LCA10 are the easiest, and is the best lead indication of the three CRISPR pure plays.
09/20/18
RAJA
09/20/18
INITIATION
RAJA
Outperform
Editas Medicine initiated with an Outperform at Raymond James
SRRK Scholar Rock
$20.63

(0.00%)

06/18/18
JEFF
06/18/18
INITIATION
Target $26
JEFF
Buy
Scholar Rock initiated with a Buy at Jefferies
Jefferies analyst Michael Yee started Scholar Rock with a Buy rating and $26 price target. Similar to other orphan drug stories, early data could offer 50%-plus upside into 2019 if they show early benefit in spinal muscular atrophy patients, Yee tells investors in a research note.
06/18/18
COWN
06/18/18
INITIATION
Target $18
COWN
Outperform
Scholar Rock initiated with an Outperform at Cowen
Cowen analyst Ritu Baral initiated Scholar Rock with an Outperform rating as she believes its lead product, SRK-015, which is a myostatin activation inhibitor in development for SMA type 2 and 3, has significant clinical promise with peak potential U.S. sales of $1.6B. Baral has an $18 price target on Scholar Rock shares.
06/18/18
BMOC
06/18/18
INITIATION
Target $31
BMOC
Outperform
Scholar Rock initiated with an Outperform at BMO Capital
BMO Capital analyst Do Kim initiated Scholar Rock with an Outperform rating and a price target of $31, citing his expectations of its proprietary research platform answering the challenges of modulating transforming growth factor beta signaling pathways. The analyst adds that the company's SRK-015 program has "properly aligned the drug's specific benefit to an ideal disease setting" and expects the Phase 1 data in Q4 to confirm its safety and PK/PD profile, with eventual proof-of-concept data coming in the second half of 2019.
06/18/18
WEDB
06/18/18
INITIATION
Target $25
WEDB
Outperform
Scholar Rock initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten started Scholar Rock with an Outperform rating and $25 price target saying it is taking a unique approach to inhibiting TGF beta, a key class of interest for drug developers but one considered too difficult to drug with specificity, by locking the proteins in their latent state. This strategy, and supportive preclinical data, give him confidence that the company's programs could be the first to safely shut down TGF beta signaling in a targeted manner, with application in several serious disorders.
IFRX InflaRx
$35.79

(0.00%)

07/13/18
BMOC
07/13/18
INITIATION
Target $45
BMOC
Outperform
InflaRx initiated with an Outperform at BMO Capital
As reported earlier, BMO Capital analyst Matthew Luchini initiated InflaRX (IFRX) with an Outperform rating and a price target of $45. The analyst notes that the company's IFX-1 "could be a best-in-class treatment for hidradenitis suppurativa" skin diseas, with initial data suggesting a "better clinical profile" than Humira. Luchini adds that the strength of IFX-1's Phase IIa data de-risks the ongoing Phase IIb trial, also stating that "IFX-1's targeting of C5a could be an advantage over emerging competitor avacopan" made by ChemoCentryx (CCXI).
12/10/18
FBCO
12/10/18
INITIATION
Target $47
FBCO
Outperform
InflaRx initiated with an Outperform at Credit Suisse
Credit Suisse analyst Tiago Fauth started coverage of InflaRx with an Outperform rating and $47 price target. The analyst believes the stock will outperform based on a favorable risk/reward into a potentially meaningfully de-risking Phase 2b clinical update for IFX-1 in HS and increasing investor recognition of the substantial and growing opportunity in the HS market.
07/13/18
BMOC
07/13/18
INITIATION
Target $45
BMOC
Outperform
InflaRx initiated with an Outperform at BMO Capital
BMO Capital analyst Matthew Luchini initiated InflaRx with an Outperform and $45 price target.
06/28/18
RHCO
06/28/18
INITIATION
Target $55
RHCO
Buy
InflaRx initiated with a Buy at SunTrust
As reported earlier, SunTrust analyst Yatin Suneja initiated InflaRx with a Buy rating and a price target of $55. The analyst says the company's only clinical candidate IFX-1 has produced "promising Phase 2a data in hidradenitis suppurativa skin disease", adding that he is optimistic about the program's success in the Phase 2b trial which is expected to yield initial data in the first half of FY19. Suneja believes that IFX-1 could achieve peak global sales of about $2B.
AMRN Amarin
$14.38

0.45 (3.23%)

01/07/19
JEFF
01/07/19
NO CHANGE
Target $30
JEFF
Buy
Jefferies keeps $30 target on Amarin, says guidance conservative
Amarin Friday night reported "strong" Q4 Vascepa results, although stock is trading lower perhaps due to conservative guidance, Jefferies analyst Michael Yee tells investors in a research note. The analyst views the news "as a positive sign of what's been going on recently." Amarin does not even have a label expansion yet and it has been only two months since the mid-November data presentation, Yee writes. He expects trends to continue to grow monthly throughout the year, even before Amarin receives a formal label expansion. While the stock may be down today, "things look strong fundamentally," Yee contends. He views the company's sales guidance as conservative and keeps a Buy rating on Amarin with a $30 price target.
01/07/19
RHCO
01/07/19
NO CHANGE
Target $15
RHCO
Buy
Amarin price target lowered to $15 from $30 at SunTrust
SunTrust analyst John Boris lowered his price target on Amarin after the company guided its FY19 revenue outlook well below consensus and offered more details timing of Vascepa sNDA filing. The analyst contends that the company needs to employ a larger sales force to "realize Vascepa full potential" beyond the 400 reps currently and also lowers his FY19 EPS view to (23c) from 18c to reflect Amarin's expectations of lower sales and higher SG&A costs. Longer term, Boris keeps his Buy rating on Amarin, noting that Vascepa could have a "significant commercial upside" if it can secure a label for reducing cardiovascular risk.
12/20/18
JEFF
12/20/18
NO CHANGE
Target $30
JEFF
Buy
Amarin shares will bounce back on 2019 catalysts, says Jefferies
After hosting meetings with management, Jefferies analyst Michael Yee says Amarin represents one of the few "de-risked" standalone blockbuster drugs in the smid-cap Biotech space. Following the stock's pullback from of $23 to $15, Amarin will "bounce and go back up," predicts the analyst. He sees 2019 catalysts from "scripts and sales ramp to FDA approval." Further, a potential takeout is a "wildcard," writes Yee in a note titled "The Big Fish In A Big Pond? Update from Mgmt Meetings..." The analyst keeps a Buy rating on Amarin with a $30 price target.
01/08/19
SBSH
01/08/19
NO CHANGE
Target $20
SBSH
Buy
Amarin price target lowered to $20 from $28 at Citi
Citi analyst Joel Beatty lowered his price target for Amarin to $20 after the company's 2019 revenue guidance came in lower than he expected. The analyst, however, continues to view Vascepa as an "attractive and differentiated cardiovascular risk reduction therapy." His peak sales estimate is now $2.5B, down from $3.0B previously.
AKBA Akebia
$6.49

-0.11 (-1.67%)

11/12/18
11/12/18
DOWNGRADE

Market Perform
Raymond James downgrades Keryx to Market Perform ahead of Akebia deal closing
As previously reported, Raymond James analyst Reni Benjamin downgraded Keryx (KERX) to Market Perform from Outperform as he sees shares trading in-line with the market until the merger with Akebia (AKBA) is complete. The potential merger with Akebia is likely to go through by year-end, Benjamin contends. The merged company is likely to become "a fully-integrated renal powerhouse," the analyst added.
08/23/18
HCWC
08/23/18
NO CHANGE
HCWC
Keryx, Akebia merger remains on track, says H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert believes the merger between Keryx Biopharmaceuticals (KERX) and Akebia Therapeutics (AKBA) remains on track. According to the Federal Trade Commission website, the status of the merger application now shows "granted," Kolbert tells investors in a research note. The analyst says that while he did not expect FTC clearance to be an issue, "it's good to see it granted." He keeps a Buy rating on Keryx with a $9 price target.
10/22/18
MZHO
10/22/18
NO CHANGE
Target $17
MZHO
Buy
Akebia 'significantly undervalued' ahead of catalysts, says Mizuho
Mizuho analyst Difei Yang views Akebia Therapeutics as "significantly undervalued" ahead of catalysts expected in 2019 including data readouts from vadadustat and launch metrics from Auryxia. The stock is one to pay attention to in 2019 following poor performance in 2018 "despite making progress in multiple pivotal trials," Yang tells investors in a research note. She lowered her price target for the shares to $17 from $21 and keeps a Buy rating on Akebia.
09/07/18
MSCO
09/07/18
INITIATION
Target $9
MSCO
Equal Weight
Akebia resumed with an Equal Weight at Morgan Stanley
Morgan Stanley analyst David Lebowitz resumed coverage of Akebia (AKBA) with an Equal Weight rating and $9 price target, stating that value is primarily driven by the potential of vadadustat as a treatment for anemia associated with chronic kidney disease. Vadadustat is a year behind FibroGen's (FGEN) competing HIF-inhibitor roxadustat and that lead could be an advantage if the data for the two drugs is not sufficiently differentiated, said Lebowitz.
PKI PerkinElmer
$79.53

0.75 (0.95%)

10/09/18
UBSW
10/09/18
INITIATION
Target $100
UBSW
Neutral
PerkinElmer initiated with a Neutral at UBS
UBS analyst Daniel Brennan initiated PerkinElmer with a Neutral rating and $100 price target.
10/09/18
UBSW
10/09/18
NO CHANGE
UBSW
UBS initiates coverage of Life Sciences and Diagnostics Tools sector
UBS analyst Daniel Brennan initiated coverage of the Life Sciences and Diagnostics Tools sector. He said demand is accelerating across his universe but valuations are extended. He expects strong fundamentals to continue into 2019 but he said selectivity is the key. In the group, his Buy ratings include Exact Sciences (EXAS), Iqvia (IQV), NanoString (NSTG), Syneos Health (SYNH) and Thermo Fisher (TMO).
11/02/18
JANY
11/02/18
DOWNGRADE
JANY
Neutral
PerkinElmer downgraded to Neutral from Buy at Janney Montgomery Scott
01/02/19
NEED
01/02/19
INITIATION
NEED
Hold
PerkinElmer initiated with a Hold at Needham
Needham analyst Stephen Unger started PerkinElmer with a Hold rating and $79 fair value estimate.
ELAN Elanco
$33.25

0.82 (2.53%)

10/15/18
COWN
10/15/18
INITIATION
Target $38
COWN
Outperform
Elanco initiated with an Outperform at Cowen
Cowen analyst Steve Scala initiated Elanco with an Outperform rating based on its top-tier position in the animal health market, an improving product portfolio, and early stages of margin improvement driving leveraged earnings growth. Scala has a $38 price target on Elanco shares.
12/19/18
BMOC
12/19/18
NO CHANGE
Target $32
BMOC
Market Perform
Elanco price target lowered to $32 from $37 at BMO Capital
BMO Capital analyst Alex Arfaei lowered his price target on Elanco (ELAN) to $32 and kept his Market Perform rating, saying its FY19 guidance was "modestly below" his expectations and that he doubts that the management is being conservative. The analyst also cites "significant uncertainties" in 2020 related to competitor's products and the company's R&D productivity, also lowering his FY19 EPS view to $1.13 from $1.22. Arfaei believes that the market valuation on Elanco similar to Zoetis (ZTS) is "premature" based on the "important differences in revenue growth potential, product mix, and execution track record" of the two companies.
10/16/18
SBSH
10/16/18
INITIATION
Target $37
SBSH
Buy
Elanco initiated with a Buy at Citi (yesterday)
Citi analyst Liav Abraham yesterday initiated coverage of Elanco Animal Health with a Buy rating and $37 price target.
10/15/18
10/15/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CalAmp (CAMP) initiated with a Hold at Jefferies. 2. Eventbrite (EB) initiated with an Outperform at RBC Capital, a Buy at Stifel, a Hold at SunTrust, as well as a Neutral at JPMorgan and Goldman Sachs. 3. X Financial (XYF) initiated with an Equal Weight at Morgan Stanley and a Hold at Deutsche Bank. 4. Bank7 (BSVN) initiated with an Outperform at Keefe Bruyette and an Overweight at Stephens. 5. Elanco (ELAN) initiated with an Outperform at Cowen, an Overweight at JPMorgan, an Equal Weight at Morgan Stanley, as well as a Neutral at Credit Suisse, BofA/Merrill, Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
XRAY Dentsply Sirona
$40.00

0.58 (1.47%)

10/19/18
10/19/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Overweight from Equal Weight at Barclays with analyst Kannan Venkateshwar saying the stock is likely to become a "core holding" again. 2. Dentsply Sirona (XRAY) double upgraded to Buy from Sell at Goldman Sachs with analyst Nathan Rich saying he now believes consensus estimates are achievable and that Dentsply's valuation is attractive relative to Medtech peers. 3. PayPal (PYPL) upgraded to Buy from Neutral at BTIG with analyst Mark Palmer saying the company's Venmo monetization progress was the deciding factor in his rating change. 4. Roku (ROKU) upgraded to Outperform from Sector Perform at RBC Capital with analyst Mark Mahaney saying the company's valuation has become more attractive following a 25% pullback in its stock price but believes Roku offers the "best opportunity for upwards estimates revisions." 5. O'Reilly Automotive (ORLY) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Horvers saying he sees "strong" fundamentals with "structurally positive industry factors." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/19/18
GSCO
10/19/18
UPGRADE
Target $44
GSCO
Buy
Dentsply Sirona upgraded to Buy from Sell at Goldman Sachs
Goldman Sachs analyst Nathan Rich double upgraded Dentsply Sirona to Buy from Sell and raised his price target for the shares to $44 from $37. Following nearly 50% underperformance year-to-date versus the S&P 500 Index, the analyst now believes consensus estimates are achievable and that Dentsply's valuation is attractive relative to Medtech peers. Further, he sees see potential value creation from additional cost savings. Dentsply at current levels offers an "attractive n entry point to own an interesting turnaround story," Rich tells investors in a research note.
12/27/18
GSCO
12/27/18
NO CHANGE
GSCO
Goldman sees potential for softer macro to weigh on U.K. dental, vet spending
Goldman Sachs analyst Nathan Rich said several recent data points, including consumer spending data and Walgreens Boots Alliance's (WBA) results, suggest a more challenging environment for U.K. consumers. Given this, he sees potential for the softer U.K. macro backdrop to weigh on spending for dental and vet services. Rich noted that Patterson (PDCO) generates the highest percentage of revenue in the U.K. among dental names he covers, at 11%, adding that Align Technology (ALGN), Henry Schein (HSIC) and Dentsply Sirona (XRAY) each have about 5% exposure on average.
01/04/19
MSCO
01/04/19
NO CHANGE
Target $210
MSCO
Equal Weight
Morgan Stanley says dental survey negative for Align, positive for Straumann
Morgan Stanley analyst Steve Beuchaw noted that the firm surveyed 30 dentists and 42 orthodontists in the U.S. and said the results points to slower aligner mix shift and emerging share movements, both of which he said are negative for Align Technology (ALGN). He further points out that the survey was run during 4Q, in advance of the full launch of competing products from 3M (MMM), Danaher (DHR) and Dentsply Sirona (XRAY). Given the survey findings, Beuchaw cut his U.S. volume estimates for Align by 400bps for 2019 and lowered his price target on the stock to $210 from $300 to account for lower estimates and a lower market multiple. He maintains an Equal Weight rating on Align Technology shares. Beuchaw added that the survey was positive for Straumann (STMN), which is covered by Michael Jungling. While investors tend to focus on new entrants from the other three mentioned above, ClearCorrect with support from Straumann was the bigger share winner prospectively in the survey, Beuchaw tells investors.
NVRO Nevro
$40.82

1.03 (2.59%)

11/07/18
11/07/18
DOWNGRADE
Target $45

Neutral
Nevro downgraded to Neutral on reduced growth at BofA/Merrill
As previously reported, BofA/Merrill downgraded Nevro to Neutral from Buy and slashed its price target to $45 from $77. Analyst Bob Hopkins said Nevro posted "strong" Q3 numbers but management comments on US volume growth in the spinal cord stimulation market were just 5-8%, causing shares to drop more than 16% yesterday. Hopkins is concerned that Nevro's outlook is much less than previously expected, and that management may have a weaker understanding on their market than anticipated.
11/27/18
UBSW
11/27/18
INITIATION
UBSW
Sell
Nevro initiated with a Sell at UBS
UBS analyst Matthew Taylor initiated Nevro with a Sell rating and $35 price target, calling the stock a Top Sell. Taylor noted that Nevro's HF10 therapy has "changed the face of neuromod," but added that it has also "spurred competition from large, entrenched players."
11/07/18
BOFA
11/07/18
DOWNGRADE
BOFA
Neutral
Nevro downgraded to Neutral from Buy at BofA/Merrill
11/27/18
11/27/18
INITIATION

Sell
Nevro initiated with a Sell at UBS
HALO Halozyme
$15.29

-0.04 (-0.26%)

11/27/18
CANT
11/27/18
NO CHANGE
Target $27
CANT
Overweight
Halozyme modified Phase 3 design 'a good thing,' says Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan reiterates an Overweight rating and $27 price target on Halozyme Therapeutics after the company announced that it has made a request to the FDA to change the dual primary endpoints of progression free survival and overall survival of the HALO-301 study to the single primary endpoint of overall survival. On the surface, this "change" can quickly lead to a negative perception of trial progress, Duncan tells investors in a research note titled "Don't Miss the Forest for the Trees - Modified P3 is a Good Thing." However, when assessing the design and rationale, in conjunction with the study remaining blinded, the analyst views the move as "prudent, with the clinical risk thus having been reduced, at least, incrementally." He believes investors appreciate the high-risk in pancreatic cancer, and therefore see low expectations for Phase 3 success being priced into the current share price. Duncan says he has "enhanced non-zero conviction" in the potential for HALO-301 to read out positively in the second half of 2019.
11/27/18
JEFF
11/27/18
NO CHANGE
Target $9
JEFF
Underperform
Jefferies still sees low likelihood of success for Halozyme's PEGPH20
Following the announced change in the Phase 3 endpoint, Jefferies analyst Eun Yang continues to view probability for success of Halozyme Therapeutics's PEGPH20 in pancreatic cancer as low. The change in the HALO-301 endpoint/data analysis "dampens our confidence further," Yang tells investors in a research note. HALO-301 is a phase 3 global, randomized, double-blind placebo controlled clinical trial evaluating investigational new drug PEGPH20 as a first-line therapy for potential treatment of patients with metastatic pancreas cancer. The analyst remains cautious on Halozyme shares with an Underpeform rating and $9 price target.
11/27/18
JMPS
11/27/18
NO CHANGE
Target $21
JMPS
Outperform
Halozyme Phase 3 trial amendment makes sense, says JMP Securities
After Halozyme announced that it is amending the design of the Phase 3 trial evaluating PEGPH20 in front-line pancreatic cancer to make overall survival the sole primary endpoint, JMP Securities analyst Jason Butler said he thinks the change makes sense and is neutral to his thesis. While the change pushes out first results by about 6-9 months, the "outcome will be definitive," said Butler, who reiterates an Outperform rating and $21 price target on Halozyme shares.
10/18/18
PIPR
10/18/18
INITIATION
Target $17
PIPR
Neutral
Halozyme assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro assumed coverage of Halozyme Therapeutics with a Neutral rating and $17 price target. While the analyst views the Enhanze technology as an "attractive platform that could drive substantial royalty revenue," he has near term concerns around the pivotal HALO-301 study. He believes HALO-301 will need to hit on both progression-free survival and overall survival to support approval and adoption, which tempers his expectations.
SNNA Sienna Biopharmaceuticals
$3.02

0.02 (0.67%)

05/15/18
BMOC
05/15/18
NO CHANGE
Target $30
BMOC
Outperform
Sienna recent pullback brings good entry point, says BMO Capital
BMO Capital analyst Gary Nachman says Sienna Biopharmaceuticals' key catalysts are getting closer following its Q1 results. The company's important data readouts over the next year, beginning in Q3, include SNA-125 for psoriasis and atopic dermatitis, SNA-001 for light hair removal and acne, and SNA-120 for pruritis, Nachman tells investors in a post-earnings research note. He continues to see a "good risk/reward" on the shares into the data catalysts and remains confident in management's ability to execute. Nachman believes recent pullback in the stock creates a good entry point and reiterates an Outperform rating on Sienna Biopharmaceuticals with a $30 price target.
10/10/18
BMOC
10/10/18
NO CHANGE
BMOC
BMO Capital confident in management, pipeline at Sienna Biopharmaceuticals
BMO Capital analyst Gary Nachman reiterated an Outperform rating on Sienna Biopharmaceuticals shares after recent investor meetings with management. The analyst is "cautiously optimistic" on SNA-001 in hair removal, sees good risk/reward for SNA-120 in pruritis associated with psoriasis and SNA-125 for atopic dermatitis, and over is "confident in management's ability to execute this pipeline with multiple shots on goal."
12/04/18
BMOC
12/04/18
NO CHANGE
Target $17
BMOC
Outperform
Sienna Biopharmaceuticals price target lowered to $17 from $27 at BMO Capital
BMO Capital analyst Gary Nachman lowered his price target on Sienna Biopharmaceuticals to $17 following its mixed Phase 2b results for SNA-120. The analyst states that the program missed the primary endpoint in pruritis, but showed surprisingly good results on key secondary endpoints in psoriasis and sees the management changing its course to focus on the psoriasis indication. Nachman keeps his Outperform rating on Sienna Biopharmaceuticals based on the potential of SNA-120 in psoriasis, even though he acknowledges its "increased development risk and questions regarding ultimate opportunity in a crowded psoriasis market".
07/31/18
BMOC
07/31/18
NO CHANGE
Target $27
BMOC
Outperform
Sienna has bigger value drivers than SNA-001 in acne, says BMO Capital
BMO Capital analyst Gary Nachman called Sienna Biopharmaceuticals' announcement that SNA-001 failed in two of its three pivotal studies in acne an "unfortunate outcome," but he believes the bigger long-term value drivers for Sienna remain SNA-001 for light-hair removal and SNA-125 for psoriasis and atopic dermatitis. After removing any SNA-001 acne revenue from his estimates, Nachman lowered his price target on Sienna Biopharmaceuticals to $27 from $30 and keeps an Outperform rating on the shares.
ACAD Acadia
$19.19

0.67 (3.62%)

12/10/18
ADAM
12/10/18
INITIATION
Target $23
ADAM
Hold
Acadia initiated with a Hold at Canaccord
Canaccord analyst Sumant Kulkarni initiated Acadia Pharmaceuticals with a Hold rating and $23 price target. In a research note to investors, Kulkarni says that while he believes Acadia is a core holding for investors seeking exposure to central nervous system, or CNS, companies with commercial assets, he believes the risk/reward on the stock is balanced ahead of potential issuance of the company's initial 2019 outlook for Nuplazid in Parkinson's Disease psychosis, or PDP, and views his sales estimate for Nuplazid as "reasonable," though he admits he has low visibility heading into the event.
11/13/18
LEER
11/13/18
INITIATION
Target $21
LEER
Market Perform
Acadia initiated with a Market Perform at Leerink
Leerink analyst Marc Goodman started Acadia with a Market Perform and $21 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding Acadia, Goodman believes Nuplazid will rebound following the negative publicity regarding its safety profile based on his proprietary MEDACorp physician survey work, but consensus now assumes a rebound.
11/07/18
HCWC
11/07/18
NO CHANGE
Target $60
HCWC
Buy
Acadia poised to outperform in 2019, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein expects to see Nuplazid regain momentum following Acadia Pharmaceuticals' Q3 results. As the overhang of the safety concerns around Nuplazid was cleared by the FDA's statement in September, the key commercial question is now whether the company will be able to regain the growth momentum through a number of promotional activities, Fein tells investors in a research note. He expects to see the "normalization of growth in the months ahead" and says Acadia is poised to outperform in 2019. Fein keeps a Buy rating on the shares with a $60 price target.
11/12/18
LEER
11/12/18
INITIATION
Target $21
LEER
Market Perform
Acadia initiated with a Market Perform at Leerink
Leerink Partners analyst Marc Goodman started Acadia Pharmaceuticals with a Market Perform rating and $21 price target.
AXDX Accelerate Diagnostics
$14.56

0.11 (0.76%)

11/07/18
JPMS
11/07/18
DOWNGRADE
Target $16
JPMS
Neutral
Accelerate Diagnostics downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Tycho Peterson downgraded Accelerate Diagnostics to Neutral and lowered his price target for the shares to $16 from $25. The analyst says Q3 did not bring what he was hoping for given "another miss and pipeline delay."
11/07/18
JPMS
11/07/18
DOWNGRADE
Target $16
JPMS
Neutral
JPMorgan downgrades Accelerate to Neutral on 'significant miss,' pipeline delay
JPMorgan analyst Tycho Peterson downgraded Accelerate Diagnostics to Neutral from Overweight and lowered his price target for the shares to $16 from $25. The company last night announced another significant miss despite again processing record-high system placement as it continues to be bottlenecked by hospital budget constraints, Peterson tells investors in a post-earnings research note. Peterson, who remains encouraged by the long-term potential of the flagship Pheno instrument, says the uptake post-launch a year ago have been much weaker than originally anticipated. In addition, despite expectations for the severe bacterial pneumonia test to start clinical trial testing in Q3, Accelerate registered "yet another delay" due to FDA pushback tied to the lack of reproducibility, and now expects to start the clinical trial in Q1 of 2019, the analyst adds. He downgrades the shares to Neutral citing "another disappointing quarter" with "yet another unexpected pipeline delay."
05/24/18
CHLM
05/24/18
INITIATION
Target $25
CHLM
Hold
Accelerate Diagnostics initiated with a Hold at Craig-Hallum
Craig-Hallum analyst Alexander Nowak started Accelerate Diagnostics with a Hold rating and $25 price target saying it will become attractive once expectations are significantly lowered, potentially by Q4.
ICPT Intercept
$112.50

1.58 (1.42%)

11/19/18
OPCO
11/19/18
UPGRADE
Target $140
OPCO
Outperform
Oppenheimer upgrades Intercept to Outperform on greater confidence in NASH
Oppenheimer analyst Jay Olson upgraded Intercept Pharmaceuticals to Outperform from Perform and raised his price target for the shares to $140 from $100. The shares closed Friday up 2%, or $1.82, to $102.70. Intercept is increasingly likely to have a first-in-class and potentially best-in-class FXR agonist for non-alcoholic steatohepatitis, Olson tells investors in a research note. The analyst left this year's American Association for the Study of Liver Diseases meeting with the perceptions that Intercept's obeticholic acid is likely to achieve statistical significant on both primary endpoints in the Regnerate trial. As such, the analyst increased his probability of success for obeticholic acid from 50% to 75% in NASH.
12/11/18
RILY
12/11/18
INITIATION
Target $155
RILY
Buy
Intercept initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Mayank Mamtani started Intercept Pharmaceuticals with a Buy rating and $155 price target.
12/12/18
RILY
12/12/18
INITIATION
RILY
B. Riley FBR rolls out coverage on NASH players with three Buy ratings
B. Riley FBR analyst Mayank Mamtani last night initiated coverage of four companies working on developing drugs to treat nonalcoholic steatohepatitis. The analyst started Galmed Pharmaceuticals (GLMD) with a Buy rating and $28 price target, Intercept Pharmaceuticals (ICPT) with a Buy rating and $155 price target, Viking Therapeutics (VKTX) with a Buy rating and $16 price target, and Madrigal Pharmaceuticals (MDGL) with a Neutral rating and $124 price target. NASH disease burden is "poised to create the next liver transplant crisis" and is drawing significant investments from the biotech industry, Mamtani writes in a research note. He points out that Intercept's obeticholic acid is the only NASH drug to have the FDA's breakthrough therapy designation for strong anti-fibrotic efficacy and be previously approved by the FDA, for an orphan liver indication. His proprietary safety analysis suggests the Street should gain comfort in drug's cardiovascular profile going into pivotal readout in Q2 of 2019. Mamtani believes Viking's lead drug, VK2809, has an "excellent" safety and tolerability profile that assuages concerns of any off-target effects. Further, his comparator analysis suggests efficacy in high-dose of Galmed's Aramchol drug "represents a compelling clinical profile on both regulatory acceptable endpoints."
12/12/18
12/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Foamix (FOMX) initiated with a Buy at BofA/Merrill. 2. Jazz Pharmaceuticals (JAZZ) initiated with an Outperform at Oppenheimer while GW Pharmaceuticals (GWPH) was initiated with a Perform. 3. Six Flags (SIX) initiated with a Buy at Berenberg. 4. iQIYI (IQ) initiated with a Hold at HSBC. 5. Intercept (ICPT), Viking Therapeutics (VKTX), and Galmed (GLMD) were initiated with a Buy at B. Riley FBR, while Madrigal Pharmaceuticals (MDGL) initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
OXFD Oxford Immunotec
$14.34

0.21 (1.49%)

02/27/18
PIPR
02/27/18
NO CHANGE
Target $15
PIPR
Overweight
Oxford Immunotec guidance 'looks beatable,' says Piper Jaffray
Piper Jaffray analyst William Quirk noted that Oxford Immunotec's Q1 revenue guidance is below consensus expectations, but he believes the company is poised to beat 2018 revenue expectations given TB headwinds that are ending and several tailwinds that are upcoming. He maintains an Overweight rating and $15 price target on Oxford shares.
11/09/18
PIPR
11/09/18
NO CHANGE
PIPR
Overweight
Oxford Immunotec price target suspended at Piper Jaffray
Piper Jaffray analyst William Quirk kept his Overweight rating on Oxford Immunotec but suspended his $14 price target after its Q3 results this morning, saying its revenues did not include the "impact of the new supplier relationship with Quest". The analyst notes that the decision further reflects his "lack of insight into future results", even though he "still expects the new Oxford model to reflect a more rapid shift to profitability."
09/25/18
PIPR
09/25/18
NO CHANGE
PIPR
Piper Jaffray confident on Oxford path to profitability after Quest deal
Piper Jaffray analyst William Quirk notes that Quest Diagnostics (DGX) announced the acquisition of the U.S. laboratory services business from Oxford Immunotec (OXFD), paying $170M for about $55M in tick-borne disease and TB revenue. The deal streamlines Oxford Immunotec into essentially a kit company with better margins and an opportunity to vie for Qiagen's attractive Quest business, he contends, adding that the TB market has been growing in the mid-teens in the U.S., largely converting existing volume from the skin test to the more accurate IGRA class of assays. Long-term, Quirk believes Oxford's revenue estimates may be more predictable than they have been in the past, and his confidence in the company's path to profitability is improved following the deal announcement.
SSNLF Samsung
$0.00

(0.00%)

01/08/19
NEED
01/08/19
NO CHANGE
NEED
Hold
Needham stays Hold on Micron, says Samsung confirmed weakening outlook
Needham analyst Rajvindra Gill keeps a Hold rating on Micron Technology (MU) after Samsung (SSNLF) lowered its preliminary outlook for Q4. Similar to Micron, Samsung cited excess inventory at its hyperscaler customers and weaker than expected demand in smartphones, Gill tells investors in a research note. Samsung also reiterated a similar view of Micron's that it expects a second half of 2019 rebound driven by new central processing unit architectures and launches of new smartphones, adds the analyst. Gill, however, believes visibility into the second half of 2019 remains limited. Based on industry conversations, he thinks excess inventory at hypersacalers will persist for at least another 3-6 months. Further, the slowing Chinese economy makes him cautious on overall demand conditions in the first half of the year. As such, Gill says that while Micron is trading at historical low valuation multiples, the stock has further downside if demand conditions worsen. Shares of Micron are down 3%, or $1.11, to $32.89 in morning trading.
12/11/18
CHLM
12/11/18
NO CHANGE
Target $28
CHLM
Buy
Xperi price target raised to $28 from $20 at Craig-Hallum
Craig-Hallum analyst Richard Shannon raised his price target for Xperi to $28 from $20 (XPER), while reiterating a Buy rating on the shares. The analyst notes that the the company's Samsung (SSNLF) settlement is a critical event in its history as it shows that its portfolio has substantial ongoing value, and that Xperi is willing to be patient to find a fair settlement.
12/10/18
BNCH
12/10/18
NO CHANGE
Target $35
BNCH
Buy
Xperi settlement removes Samsung uncertainty, says Benchmark
After Xperi (XPER) announced a patent license agreement with Samsung (SSNLF) that it said settles all outstanding legal matters between the parties, Benchmark analyst Gary Mobley said he believes the pact "removes nearly all of the uncertainty that has plagued the shares during the past two years." He raised his price target on Xperi shares to $35 from $25 to account for his higher FY19 estimates and keeps an Buy rating on the stock, which he still views as undervalued.
01/09/19
ADAM
01/09/19
NO CHANGE
Target $84
ADAM
Buy
Skyworks price target lowered to $84 from $96 at Canaccord
Canaccord analyst T. Michael Walkley lowered his price target on Skyworks (SWKS) to $84 from $96 following its preannouncement indicating weak smartphone sales from its leading customers, Apple (AAPL) and Samsung (SSNLF), would lead to lower revenues. The analyst also lowered his estimates due to weak global trends including Android smartphones. He still believes, however, that the company's diverse portfolio positions its broad market division for double digit annual growth and Walkley maintained his Buy rating on Skyworks shares.
MDSO Medidata
$68.18

1.28 (1.91%)

01/02/19
01/02/19
NO CHANGE
Target $70

Market Perform
Leerink says expectations high for Medidata, initiates with Market Perform
As previously reported, Leerink analyst David Larsen started Medidata with a Market Perform Rating and a $70 price target. The analyst likes how the company is considered to be the premium solution with respect to clinical trial electronic data capture. But while the fundamentals of the industry and company are favorable, Larsen thinks there is significant risk to the stock. The overall market has been volatile which will pressure higher multiple stocks, and investor expectations for revenue growth are very high and any disappointment could result in a significant sell-off, he contents. Further, the analyst believes 95%-plus of biopharma already have electronic clinical solutions in place, and the market is becoming more competitive.
01/02/19
LEER
01/02/19
INITIATION
LEER
Market Perform
Medidata initiated with a Market Perform at Leerink
12/13/18
JPMS
12/13/18
DOWNGRADE
Target $74
JPMS
Underweight
Medidata downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Sterling Auty downgraded Medidata Solutions to Underweight with an unchanged price target of $74. The analyst points out that only 2% upside remains to his fair value price target. Medidata needs to see improved execution consistency in sales to drive up estimates, Auty tells investors in a research note.
01/04/19
PIPR
01/04/19
NO CHANGE
Target $83
PIPR
Overweight
Medidata price target lowered to $83 from $93 at Piper Jaffray
Piper Jaffray analyst Sean Wieland lowered his price target for Medidata Solutions to $83 while keeping an Overweight rating on the name. The analyst reduced his 2019 revenue estimates to factor in management's clarifying remarks about the impact of the Shyft acquisition. Wieland continues to like the company's growth prospects, but would "tread lightly" into its 2019 guidance to be issued on the Q4 earnings call.
WELL Welltower
$69.75

-0.5 (-0.71%)

12/05/18
MUFG
12/05/18
NO CHANGE
MUFG
Welltower price target raised to $76 from $72 at MUFG
MUFG analyst Karin Ford maintained an Overweight rating on Welltower, and raised her price target on shares to $76 from $72, following Welltower's 2018 Investor Day. Ford said of the meeting, "We were encouraged by management's 12.7% 5-year total annualized return forecast. Moreover, average annual organic cash flow growth of 5.6% and a 5.0% dividend yield implies a double-digit return for shareholders without any incremental capital activity. Management seemed bullish on investments, which are supported by a strong balance sheet and data analytic platform, as well as on senior housing prospects, where the impact of supply may decline 23% next year."
12/10/18
SCOT
12/10/18
INITIATION
Target $74
SCOT
Sector Perform
Welltower initiated with a Sector Perform at Scotiabank
Scotiabank analyst Nicholas Yuico initiated Welltower with a Sector Perform and $74 price target.
12/19/18
JPMS
12/19/18
UPGRADE
Target $76
JPMS
Overweight
Welltower upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anthony Paolone upgraded Welltower to Overweight and raised his price target for the shares to $76 frmo $74. The analyst sees it as a positive that the company is being more acquisitive again. Further, most of Welltower's "major dilutive" asset sales/portfolio restructurings seem to be finished at this point as well, Paolone tells investors in a research note.
12/11/18
WELS
12/11/18
UPGRADE
Target $79
WELS
Outperform
Welltower upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Todd Stender upgraded Welltower to Outperform from Market Perform and raised his price target on the shares to $79 from $68. For some time, dilutive asset sales from the company's efforts to reduce tenant concentration and exposure to Genesis Healthcare kept him at bay with his more neutral rating. Now, with much of those initiatives in the rearview mirror and external growth very much back to Welltower's old pace, the analyst views the shares as warranting his highest rating as the company's cost of equity has improved throughout 2018, thus potentially providing it with the fuel to be acquisitive during this period of senior housing and skilled nursing operator dislocation, which could present incremental healthcare real estate acquisition opportunities.
OMCL Omnicell
$64.44

0.65 (1.02%)

10/26/18
CANT
10/26/18
NO CHANGE
Target $70
CANT
Overweight
Omnicell price target raised to $70 from $63 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper raised his price target for Omnicell to $70 and reiterates an Overweight rating on the shares following the company's Q3 results. The analyst remain bullish on Omnicell's long-term growth outlook and believes it fundamentals are improving.
12/07/18
CANT
12/07/18
NO CHANGE
Target $80
CANT
Overweight
Omnicell price target raised to $80 from $70 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper raised his price target for Omnicell to $80 and reiterates an Overweight rating on the shares after attending the mid-year meeting of the American Society of Health-System Pharmacists. It appears Omnicell is making good progress with its XR2 and IVX automation products, Halper tells investors in a research note. He believes the company is "certainly creating more value for its health system customers."
12/07/18
OPCO
12/07/18
NO CHANGE
Target $86
OPCO
Outperform
Omnicell price target raised to $86 from $73 at Oppenheimer
Oppenheimer analyst Mohan Naidu reiterated an Outperform rating on Omnicell and raised his price target to $86 following discussions with management and new product reviews at an industry conference. In a research note to investors, Naidu says the Performance Center is gaining traction and has the potential to save 2-3% of annually on Rx spend. Management also noted that XT is in the early innings of the conversion cycle, while XR2 can handle greater than 90% of Rx vs. competitive models ~50-60% and installations are on track for Q4.
01/04/19
OPCO
01/04/19
NO CHANGE
Target $31
OPCO
Outperform
Healthcare IT pullbacks create 'great' opportunities, says Oppenheimer
Oppenheimer analyst Mohan Naidu says that recent pullbacks are creating some "great" opportunities in Healthcare IT and believes, in particular, Evolent Health (EVH), Omnicell (OMCL), Tabula Rasa HealthCare (TRHC) and Teledoc (TDOC) stand out. In a research note to investors, Naidu contends that Evolent will gain from the finalized CMS regulations and increased push to risk-based models, and says Omnicell's story is significantly de-risked with traction in XT implementations. He also adds that Tabula Rasa should deliver on multiple growth drivers brewing in 2019 including PACE. and that despite the near-term distractions, Teledoc's story remains intact with significant telehealth adoption and utilization focus.
LJPC La Jolla
$6.00

0.56 (10.29%)

07/27/18
HCWC
07/27/18
NO CHANGE
Target $53
HCWC
Buy
La Jolla price target lowered to $53 from $72 at H.C. Wainwright
H.C. Wainwright analyst Edward White lowered his price target for La Jolla Pharmaceutical to $53 as he moves Giapreza out of pipeline estimates and utilizes a sum-of-the-parts analysis. The analyst keeps a Buy rating on the shares.
08/09/18
RHCO
08/09/18
NO CHANGE
Target $45
RHCO
Buy
La Jolla price target lowered to $45 from $57 at SunTrust
SunTrust analyst Yatin Suneja lowered his price target on La Jolla to $45 after its Q2 sales of Giapreza came in "significantly" below expectations, reflecting the "hurdles of navigating complex hospital adoption". Longer term, the analyst keeps his Buy rating on the shares given his view of Giapreza as a " true value-add in the treatment of septic shock".
10/25/18
HCWC
10/25/18
NO CHANGE
Target $48
HCWC
Buy
La Jolla price target lowered to $48 from $53 at H.C. Wainwright
H.C. Wainwright analyst Edward White lowered his price target for La Jolla Pharmaceutical to $48 citing a reduced estimated sales ramp of Giapreza following the company's Q3 results. The analyst keeps a Buy rating on the shares.
01/09/19
HCWC
01/09/19
NO CHANGE
Target $25
HCWC
Buy
La Jolla price target lowered to $25 from $48 at H.C. Wainwright
H.C. Wainwright analyst Edward White lowered his price target for La Jolla Pharmaceutical to $25 saying Giapreza guidance fell short of his expectations. The analyst, however, keeps a Buy rating on the shares.
ARAY Accuray
$3.70

0.08 (2.21%)

11/01/18
SBSH
11/01/18
UPGRADE
Target $3.9
SBSH
Neutral
Accuray upgraded to Neutral from Sell at Citi
Citi analyst Amit Hazan upgraded Accuray to Neutral and raised his price target for the shares to $3.90 from $3.50. The "long-anticipated" China quota announcement for the radiation therapy market came in well above expectations at 1,396 total systems, Hazan tells investors in a research note. He expects Accuray is now positioned to deliver above Street orders over the coming few years given its "prior success with Type A tenders in China last quota cycle." However, the analyst believes risks still remain in China around actual license award/allocation, new competition, and conversion of these orders into revenues.
04/10/18
RBCM
04/10/18
NO CHANGE
Target $6
RBCM
Sector Perform
Accuray can execute on replacement cycle, says RBC Capital
RBC Capital analyst Brandon Henry writes that the findings from his Radiation Oncologist survey suggest Accuray "can execute on its replacement cycle opportunity", but the company has to do more to convince the practitioners outside its installed base that its systems are sufficiently differentiated. Henry adds that the replacement cycle opportunity for Accuray's CyberKnife remains intact, with a more positive response rate by oncologists in Europe, though U.S. oncologists were less enthused in their response. The analyst keeps his Sector Perform rating and $6 price target on Accuray, forecasting the stock to perform in line with its peer group.
LMNX Luminex
$24.56

0.33 (1.36%)

05/07/18
DBAB
05/07/18
UPGRADE
Target $22
DBAB
Hold
Luminex upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Dan Leonard upgraded Luminex to Hold and raised his price target for the shares to $22 from $19. The analyst views the risk/reward as balanced at current share levels.
09/27/18
PIPR
09/27/18
NO CHANGE
PIPR
Neutral
Piper says about $3.5M of Luminex revenue at risk from Medicare determination
After Palmetto's MolDx released a final local coverage determination that panels of 3-5 pathogens will be covered, but larger panels will not be, Piper Jaffray analyst William Quirk said he believes 51% of the population is covered by MACs that follow MolDX. In terms of the decision's implications for Luminex, Quirk said he sees $3M-$4M in exposure to MolDx Medicare for Luminex's xTAG and Nanosphere tests. He also noted that Luminex management has talked about unbundling to make their panels smaller, which he believes will be the likely outcome. Quirk has a Neutral rating on Luminex shares.

TODAY'S FREE FLY STORIES

EVA

Enviva

$28.75

-0.25 (-0.86%)

19:17
02/20/19
02/20
19:17
02/20/19
19:17
Earnings
Enviva Partners reports Q4 EPS 28c, consensus 34c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

UBER

Uber

$0.00

(0.00%)

19:09
02/20/19
02/20
19:09
02/20/19
19:09
Periodicals
Uber to lower food delivery fees in U.K., Ireland, FT reports »

Uber will lower fees for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAR

Avis Budget

$29.35

-0.23 (-0.78%)

, SRCI

SRC Energy

$4.59

0.12 (2.68%)

19:02
02/20/19
02/20
19:02
02/20/19
19:02
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Avis…

CAR

Avis Budget

$29.35

-0.23 (-0.78%)

SRCI

SRC Energy

$4.59

0.12 (2.68%)

ALB

Albemarle

$82.82

-0.305 (-0.37%)

CDE

Coeur Mining

$5.55

0.045 (0.82%)

PEGA

Pegasystems

$59.39

0.95 (1.63%)

JACK

Jack in the Box

$78.95

-2 (-2.47%)

SAM

Boston Beer

$267.95

-0.97 (-0.36%)

GHDX

Genomic Health

$83.70

1.11 (1.34%)

NTES

NetEase

$232.66

3.11 (1.35%)

LOPE

Grand Canyon

$97.13

0.18 (0.19%)

SNPS

Synopsys

$102.98

1.08 (1.06%)

ET

Energy Transfer LP

$15.51

-0.13 (-0.83%)

CAKE

Cheesecake Factory

$46.42

-0.07 (-0.15%)

NE

Noble Corp.

$3.32

0.17 (5.40%)

FL

Foot Locker

$60.00

0.12 (0.20%)

CBLK

Carbon Black

$16.47

0.13 (0.80%)

SPTN

SpartanNash

$21.98

-0.25 (-1.12%)

VIPS

Vipshop

$7.30

0.35 (5.04%)

FLS

Flowserve

$47.75

0.485 (1.03%)

EVTC

Evertec

$30.65

0.3 (0.99%)

CONE

CyrusOne

$57.19

-0.46 (-0.80%)

XEC

Cimarex Energy

$76.38

1.3 (1.73%)

XPER

Xperi

$23.18

0.36 (1.58%)

SM

SM Energy

$19.70

0.61 (3.20%)

A

Agilent

$78.56

1.08 (1.39%)

PI

Impinj

$19.30

1.39 (7.76%)

QEP

QEP Resources

$8.19

-0.08 (-0.97%)

NUVA

NuVasive

$55.47

-1.81 (-3.16%)

ICLR

Icon

$145.61

0.28 (0.19%)

NDSN

Nordson

$138.81

-0.42 (-0.30%)

SEDG

SolarEdge

$41.48

-1.87 (-4.31%)

RBBN

Ribbon Communications

$6.06

-0.08 (-1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 01

    Mar

  • 03

    Mar

  • 03

    Mar

  • 04

    Mar

  • 04

    Mar

  • 05

    Mar

  • 06

    Mar

  • 06

    Mar

  • 06

    Mar

  • 06

    Mar

  • 08

    Mar

  • 11

    Mar

  • 11

    Mar

  • 12

    Mar

  • 13

    Mar

  • 13

    Mar

  • 14

    Mar

  • 17

    Mar

  • 20

    Mar

  • 21

    Mar

  • 27

    Mar

  • 28

    Mar

  • 28

    Mar

  • 22

    May

  • 22

    May

  • 18

    Jun

  • 16

    Jul

  • 17

    Jul

  • 26

    Sep

  • 27

    Sep

VMI

Valmont

$139.23

1.56 (1.13%)

18:55
02/20/19
02/20
18:55
02/20/19
18:55
Earnings
Valmont sees FY19 EPS $8.10-$8.90, consensus $8.56 »

Sees FY19 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

VMI

Valmont

$139.23

1.56 (1.13%)

18:51
02/20/19
02/20
18:51
02/20/19
18:51
Earnings
Valmont reports Q4 adjusted EPS $1.87, consensus $1.90 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

GOOG

Alphabet

$1,113.91

-4.25 (-0.38%)

, GOOGL

Alphabet Class A

$1,120.60

-5.83 (-0.52%)

18:46
02/20/19
02/20
18:46
02/20/19
18:46
Periodicals
Google acquires more office space in Austin, Texas, SVBJ reports »

Alphabet's Google is…

GOOG

Alphabet

$1,113.91

-4.25 (-0.38%)

GOOGL

Alphabet Class A

$1,120.60

-5.83 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 03

    Mar

  • 18

    Mar

PAAS

Pan American Silver

$14.68

-0.4 (-2.65%)

18:37
02/20/19
02/20
18:37
02/20/19
18:37
Hot Stocks
Breaking Hot Stocks news story on Pan American Silver »

Pan American Silver sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 24

    Feb

  • 24

    Feb

PAAS

Pan American Silver

$14.68

-0.4 (-2.65%)

18:36
02/20/19
02/20
18:36
02/20/19
18:36
Earnings
Pan American Silver reports Q4 adjusted EPS (1c), consensus 4c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 24

    Feb

  • 24

    Feb

ARGO

Argo Group

$69.17

0.15 (0.22%)

18:25
02/20/19
02/20
18:25
02/20/19
18:25
Hot Stocks
Argo Group raises quarterly dividend to 31c per share from 27c »

The cash dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Shares

$126.47

-0.23 (-0.18%)

18:23
02/20/19
02/20
18:23
02/20/19
18:23
Hot Stocks
SPDR Gold Shares holdings rise to 794.50MT from 792.45MT »

This is the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SP

SP Plus Corp.

$36.62

0.15 (0.41%)

18:20
02/20/19
02/20
18:20
02/20/19
18:20
Earnings
SP Plus Corp. sees FY19 EPS $2.56-$2.66, consensus $2.59 »

Sees FY19 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

GM

General Motors

$39.96

0.43 (1.09%)

, VLKAY

Volkswagen

$0.00

(0.00%)

18:20
02/20/19
02/20
18:20
02/20/19
18:20
Periodicals
Austria's Kurz says Trump, EU far apart on auto tariffs, Bloomberg says »

Austrian Chancellor…

GM

General Motors

$39.96

0.43 (1.09%)

VLKAY

Volkswagen

$0.00

(0.00%)

NSANY

Nissan

$0.00

(0.00%)

F

Ford

$8.94

0.115 (1.30%)

FCAU

Fiat Chrysler

$15.04

0.2 (1.35%)

HMC

Honda

$27.61

0.05 (0.18%)

TM

Toyota

$122.81

1.28 (1.05%)

DDAIF

Daimler AG

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 04

    Mar

  • 27

    Mar

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

SP

SP Plus Corp.

$36.62

0.15 (0.41%)

18:18
02/20/19
02/20
18:18
02/20/19
18:18
Earnings
SP Plus reports Q4 adjusted EPS 57c, consensus 48c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

LBY

Libbey

$5.75

0.15 (2.68%)

18:14
02/20/19
02/20
18:14
02/20/19
18:14
Earnings
Libbey sees FY19 revenue increase in low single digits, one estimate $806.6M »

Sees FY19 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

LBY

Libbey

$5.75

0.15 (2.68%)

18:13
02/20/19
02/20
18:13
02/20/19
18:13
Earnings
Libbey reports Q4 EPS (18c), two estimates 24c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

NTES

NetEase

$232.66

3.11 (1.35%)

18:07
02/20/19
02/20
18:07
02/20/19
18:07
Hot Stocks
NetEase reports Q4 online game service revenues up 37.7% at $1.6B »

Reports Q4 e-commerce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

NTES

NetEase

$232.66

3.11 (1.35%)

18:05
02/20/19
02/20
18:05
02/20/19
18:05
Hot Stocks
NetEase declares Q4 quarterly dividend of 48c vs 45c in Q3 »

The dividend is expected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

NTES

NetEase

$232.66

3.11 (1.35%)

18:04
02/20/19
02/20
18:04
02/20/19
18:04
Earnings
NetEase reports Q4 EPS $2.66, consensus $1.54 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

LEE

Lee Enterprises

$2.61

0.01 (0.38%)

18:04
02/20/19
02/20
18:04
02/20/19
18:04
Hot Stocks
Lee Enterprises board approves $10M stock repurchase program »

Lee Enterprises announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRNY

Kearny Financial

$13.48

-0.01 (-0.07%)

18:03
02/20/19
02/20
18:03
02/20/19
18:03
Hot Stocks
Kearny Financial raises quarterly dividend to 6c per share from 5c »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$53.43

0.11 (0.21%)

18:02
02/20/19
02/20
18:02
02/20/19
18:02
Earnings
Breaking Earnings news story on Copart »

Copart reports Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 05

    Mar

CE

Celanese

$102.65

1.71 (1.69%)

18:02
02/20/19
02/20
18:02
02/20/19
18:02
Hot Stocks
Celanese raises Acetyl Intermediates price by 5c per lb »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$53.43

0.11 (0.21%)

18:01
02/20/19
02/20
18:01
02/20/19
18:01
Earnings
Copart reports Q2 EPS 55c, consensus 51c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 05

    Mar

WPG

Washington Prime

$5.77

(0.00%)

17:50
02/20/19
02/20
17:50
02/20/19
17:50
Earnings
Breaking Earnings news story on Washington Prime »

Washington Prime sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

CPA

Copa Holdings

$89.89

-0.8 (-0.88%)

, GE

General Electric

$10.10

-0.03 (-0.30%)

17:49
02/20/19
02/20
17:49
02/20/19
17:49
Hot Stocks
Copa Airlines picks GE Aviation for digital records management »

Copa Airlines (CPA) has…

CPA

Copa Holdings

$89.89

-0.8 (-0.88%)

GE

General Electric

$10.10

-0.03 (-0.30%)

BA

Boeing

$421.61

5.21 (1.25%)

ERJ

Embraer

$20.52

-0.14 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 26

    Feb

  • 11

    Mar

  • 12

    Mar

  • 14

    Mar

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.